Diplomat Pharmacy Faces Shareholder Suit Over Value Drop
Specialty drugmaker Diplomat Pharmacy Inc. overestimated its hepatitis C drug's financial outlook and failed to properly calculate $8 million in Medicare fees, causing share values to plummet by 42 percent once...To view the full article, register now.
Already a subscriber? Click here to view full article